Patents by Inventor Cassandra VAN KRINKS

Cassandra VAN KRINKS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-PD-L1 and IL-2 cytokines
    Patent number: 11965026
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: April 23, 2024
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen Douglas Gillies
  • MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
    Publication number: 20230312720
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: September 1, 2022
    Publication date: October 5, 2023
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Ian KIRBY, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • TIGIT ANTIBODIES, ENCODING NUCLEIC ACIDS AND METHODS OF USING SAID ANTIBODIES IN VIVO
    Publication number: 20230192847
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: July 15, 2022
    Publication date: June 22, 2023
    Inventors: Joana de Abreu CARVALHO, Rachael Jane KIMBER, Jamie Ian CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE, Stephen Douglas GILLIES
  • MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
    Publication number: 20230192859
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: June 20, 2017
    Publication date: June 22, 2023
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • ANTI-ICOS ANTIBODIES
    Publication number: 20220403029
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: April 22, 2022
    Publication date: December 22, 2022
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • ANTI-ICOS ANTIBODIES
    Publication number: 20220380467
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: April 22, 2022
    Publication date: December 1, 2022
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • ANTAGONISTS ANTI-CD7 ANTIBODIES
    Publication number: 20220324968
    Abstract: The invention relates to Cluster of Differentiation 7 (CD7) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 13, 2022
    Inventors: E-Chiang LEE, Gwenoline BORHIS, Cassandra VAN KRINKS, Lucy HEPBURN, Luke BAYLISS, Miha KOSMAC
  • TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo
    Patent number: 11440960
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 13, 2022
    Assignee: KYMAB LIMITED
    Inventors: Joana de Abreu Carvalho, Rachael Jane Kimber, Jamie Ian Campbell, Nikole Sandy, Cassandra Van Krinks, Stephen John Arkinstall, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Matthew John McCourt, Richard Charles Alfred Sainson, Mohammed Hanif Ali, E-Chiang Lee, Stephen Douglas Gillies
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20210380699
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: April 28, 2021
    Publication date: December 9, 2021
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • MULTISPECIFIC ANTIBODY WITH COMBINATION THERAPY FOR IMMUNO-ONCOLOGY
    Publication number: 20200190191
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: December 19, 2017
    Publication date: June 18, 2020
    Inventors: Jamie Iain CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • ANTIBODIES
    Publication number: 20200131267
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2018
    Publication date: April 30, 2020
    Inventors: Joana de Abreu CARVALHO, Rachael Jane KIMBER, Jamie Ian CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE, Stephen Douglas GILLIES
  • Antibodies and immunocytokines
    Patent number: 10604576
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: March 31, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • ANTI-PD-L1 AND IL-2 CYTOKINES
    Publication number: 20190338032
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2017
    Publication date: November 7, 2019
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, IAN KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stphen Douglas GILLIES
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20190330351
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 31, 2019
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • ANTI-ICOS ANTIBODIES
    Publication number: 20190330345
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: August 9, 2017
    Publication date: October 31, 2019
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
    Publication number: 20190202917
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: June 20, 2017
    Publication date: July 4, 2019
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • Anti-ICOS antibodies
    Patent number: 9957323
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: May 1, 2018
    Assignee: Kymab Limited
    Inventors: Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Nikole Sandy, Cassandra Van Krinks, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen D. Gillies
  • ANTI-ICOS ANTIBODIES
    Publication number: 20180066058
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: September 7, 2017
    Publication date: March 8, 2018
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen D. GILLIES
  • ANTIBODIES AND IMMUNOCYTOKINES
    Publication number: 20170362321
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: April 6, 2017
    Publication date: December 21, 2017
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • Antibodies and immunocytokines
    Patent number: 9617338
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: April 11, 2017
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher